The potential health and economic impact of improving stroke care standards for Australia

Abstract

Background

Evidence of the burden of suboptimal stroke care should expedite quality improvement. We aimed to estimate the health and economic impact of improving acute stroke management to best practice standards using Australia as a case study.

Methods

Hospital performance in Australia was estimated using data from the National Stroke Audit of Acute Services 2013. The percentage of patients provided evidence-based therapies in all hospitals was compared to that achieved in the aggregate of top performing benchmark hospitals (that included between them, a minimum contribution of 15% of all cases audited). The number of additional patients who would receive therapies if this performance gap was rectified was applied to a standardized economic simulation model that comprised stroke rates and resource-use estimates from the North East Melbourne Stroke Incidence Study applied to the 2013 Australian population.

Results

In 2013, 41,398 patients were estimated to have been hospitalized with stroke. If acute care was improved to that of Australian benchmarks, there would be an additional 15,317 patients accessing stroke units; 1960 receiving thrombolysis; and 4007 being treated with antihypertensive medication, 3082 with antiplatelet medication, 2179 with anticoagulant medication, and 3514 with lipid-lowering therapy. Approximately 9329 disability-adjusted life years could be avoided. This additional care provided would be cost effective at AUD 3304 per disability adjusted life year avoided.

Conclusion

The benefits of reducing evidence–practice gaps in Australia are considerable. Further investment in initiatives to optimize hospital care is justified.

Keywords

Stroke benchmarking health outcomes resource use

Get full access to this article

View all access options for this article.

References

Australian Institute of Health and Welfare. 2008. Australia’s Health 2008. http://www.aihw.gov.au/publication-detail/?id=6442468102 (accessed February 2017).

Deloitte Access Economics. 2013. The economic impact of stroke in Australia. https://strokefoundation.com.au/what-we-do/research/economic-impact-of-stroke-in-australia (accessed February 2017).

Gloede

Halbach

Thrift

et al.

Long-term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study. Stroke 2014; 45: 3389–3394.

National Stroke Foundation. Clinical Guidelines for Stroke Management 2010. https://informme.org.au/guidelines/clinical-guidelines-for-stroke-management-2010 (accessed February 2017).

Donnan

Fisher

Macleod

Davis

. Stroke. Lancet 2008; 371: 1612–1623.

Eissa

Krass

Bajorek

. Use of medications for secondary prevention in stroke patients at hospital discharge in Australia. Int J Clin Pharm 2014; 36: 384–393.

Australian Commission on Safety and Quality in Health Care. Acute stroke clinical care standard. Sydney: ACSQHC. http://www.safetyandquality.gov.au/our-work/clinical-care-standards/acute-stroke-clinical-care-standard/ (2015, accessed February 2017).

Thrift

Kim

Douzmanian

et al.

Discharge is a critical time to influence 10–year use of secondary prevention therapies for stroke. Stroke 2014; 45: 539–544.

Kleinig T. Antihypertensive treatment should be commenced in hospital after stroke: Pro. Int J Stroke 2017; 12: 121–122.

10.

Mihalopoulos

Cadilhac

Moodie

et al.

Development and application of Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS): an Australian economic model for stroke. Int J Technol Assess Health Care 2005; 21: 499–505.

11.

Thrift

Dewey

Macdonell

RAL

et al.

Incidence of the major stroke subtypes: initial findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001; 32: 1732–1738.

12.

Thrift

Dewey

Sturm

et al.

Greater incidence of both fatal and nonfatal strokes in disadvantaged areas: the Northeast Melbourne Stroke Incidence Study. Stroke 2006; 37: 877–882.

13.

Cadilhac

Lannin

Anderson

et al.

Protocol and pilot data for establishing the Australian Stroke Clinical Registry. Int J Stroke 2010; 5: 217–226.

14.

National Stroke Foundation. National stroke audit—acute services clinical audit report 2013, Melbourne: National Stroke Foundation, 2014, https://informme.org.au/en/stroke-data/Acute-audits (accessed February 2017).

15.

National Stroke Foundation. National stroke audit—acute services clinical audit report 2015. Melbourne: National Stroke Foundation, 2015, https://informme.org.au/en/stroke-data/Acute-audits (accessed February 2017).

16.

Andrew

Kilkenny

Harris

et al.

Outcomes for people with atrial fibrillation in an Australian National Audit of Stroke Care. Int J Stroke 2014; 9: 270–277.

17.

Hall

Khan

Bayley

et al.

Benchmarks for acute stroke care delivery. Int J Qual Health Care 2013; 25: 710–718.

18.

Stecksen

Asplund

Appelros

et al.

Thrombolytic therapy rates and stroke severity: an analysis of data from the Swedish stroke register (Riks-Stroke) 2007–2010. Stroke 2012; 43: 536–538.

19.

Ovbiagele

Schwamm

Smith

et al.

Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke 2010; 41: 1508–1513.

20.

Cadilhac

Carter

Thrift

Dewey

. Estimating the long-term costs of ischemic and hemorrhagic stroke for australia: new evidence derived from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2009; 40: 915–921.

21.

Murray

. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994; 72: 429–445.

22.

Hong

K-S

Saver

. Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke 2010; 41: 471–477.

23.

Moodie ML. Trial application of a Model of Resource Utilisation, Costs and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Doctorate of Public Health. The University of Melbourne, Melbourne, Australia, 2003.

24.

Moodie

Cadilhac

Pearce

et al.

Economic evaluation of Australian stroke services: a prospective, multicenter study comparing dedicated stroke units with other care modalities. Stroke 2006; 37: 2790–2795.

25.

Tan Tanny

Busija

Liew

et al.

Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center. Stroke 2013; 44: 2269–2274.

26.

Ademi

Reid

Hollingsworth

et al.

Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH registry. Clin Ther 2011; 33: 1456–1465.

27.

Langhorne

. Organized inpatient (stroke unit) care for stroke. Stroke 2014; 45: e14–e15.

28.

Emberson

Lees

Lyden

et al.

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–1935.

29.

Lakhan

Sapko

. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med 2009; 2: 30.

30.

Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388: 365–375.

31.

Saxena R and Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004; 18: CD000187.

32.

Manktelow BN and Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009; 8: CD002091.

33.

Marseille

Larson

Kazi

et al.

Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 2015; 93: 118–124.

34.

Purvis

Moss

Denisenko

et al.

Implementation of evidence-based stroke care: enablers, barriers, and the role of facilitators. J Multidiscip Healthc 2014; 7: 389–400.

35.

Bray

Straney

Barger

Finn

. Effect of public awareness campaigns on calls to ambulance across Australia. Stroke 2015; 46: 1377–1380.

36.

Branagan

Hill

Salama

et al.

An evaluation of the impact of the strokelink program in Queensland: perceptions of participants. Cerebrovasc Dis 2016; 42: 139.

37.

Cobiac

Magnus

Barendregt

et al.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health 2012; 12: 1–10.

38.

Reeves

Grau-Sepulveda

Fonarow

et al.

Are quality improvements in the get with the guidelines-stroke program related to better care or better data documentation?

Circ Cardiovasc Qual Outcomes 2011; 4: 503–511.

39.

Cadilhac DA LN, Anderson CS, Kim J, et al. The Australian Stroke Clinical Registry Annual Report 2014. Report no. 6, December 2015. The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, http://www.auscr.com.au/2016/04/04/2014-annual-report/ (accessed February 2017).

40.

Ntaios

Papavasileiou

Diener

H-C

et al.

Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298–3304.

41.

Harrington

Armstrong

Nolan

Malone

. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013; 44: 1676–1681.

42.

Smith

Schwamm

. Endovascular clot retrieval therapy: implications for the organization of stroke systems of care in North America. Stroke 2015; 46: 1462–1467.

43.

Timbie

Hayward

Vijan

. Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes. Health Serv Res 2010; 45: 437–456.

44.

Krueger

Lindsay

Cote

et al.

Cost avoidance associated with optimal stroke care in Canada. Stroke 2012; 43: 2198–2206.